Altimmune, a clinical-stage biopharmaceutical company based in Gaithersburg, Maryland, has announced positive topline results from its Phase 2 RECLAIM clinical trial evaluating pemvidutide for the treatment of alcohol use disorder (AUD). The data, released on Tuesday, indicate that the investigational drug, a dual agonist of the glucagon-like peptide-1 (GLP-1) and glucagon receptors, successfully met its […]
Included Health, a prominent provider of healthcare navigation and virtual care services, announced on Tuesday a definitive agreement to acquire Firefly Health, a Massachusetts-based primary care and health plan provider, in a move designed to accelerate the delivery of comprehensive, primary-care-led health insurance alternatives for employers. The acquisition represents a significant consolidation in the digital […]
Throne Science, a health-technology startup headquartered in Austin, Texas, has successfully closed a $10 million Series A funding round to accelerate the development and distribution of its innovative AI-integrated toilet sensor. The funding round, led by Will Ventures, brings the company’s total capital raised to nearly $18 million. Other notable participants in the round include […]
The healthcare insurance landscape is currently undergoing a significant strategic realignment as payers navigate the complexities of Utilization Management (UM) and Case Management (CM). A growing consensus among industry leaders suggests a hybrid approach to medical necessity reviews: moving routine, high-volume UM tasks in-house while delegating complex, high-stakes specialty care—particularly Neonatal Intensive Care Unit (NICU) […]
The United States healthcare system is approaching a critical juncture that threatens the fundamental safety and efficacy of inpatient care. According to a 2025 study published in JAMA Network Open, average hospital occupancy rates in the U.S. have surged to 75%, representing a significant 11-percentage-point increase from the pre-pandemic baseline of approximately 64%. If current […]
The Dutch biotechnology giant Argenx has officially announced a definitive agreement to acquire Forte Biosciences for approximately $2.2 billion, marking a significant strategic pivot from its established focus on rare diseases toward more prevalent autoimmune conditions. The deal, which represents Argenx’s first major acquisition, centers on the integration of FB102, a first-in-class monoclonal antibody targeting […]
The healthcare industry’s transition toward value-based care has long been framed through the lens of reimbursement reform, but Lakshmi Halasyamani, M.D., Chief Clinical Officer at Endeavor Health, argues that this perspective is fundamentally flawed. Speaking on the current state of the industry, Halasyamani emphasized that value-based care (VBC) has become one of the most misunderstood […]
Prior authorization, once a localized administrative hurdle designed to control healthcare costs, has evolved into one of the industry’s most significant financial and operational bottlenecks. What began as a tool for insurers to ensure medical necessity has transformed into a complex web of requirements that affects hospital systems, physician practices, and, most critically, patient outcomes. […]
The American healthcare landscape is currently undergoing a seismic shift in its underlying economic foundations, forcing community and mid-sized hospitals to navigate an increasingly treacherous financial environment. For decades, these institutions relied on a predictable "cross-subsidization" model, where higher reimbursements from commercial insurance providers effectively covered the shortfalls generated by government payers and uncompensated care. […]
Crystalys Therapeutics, a San Diego-based biopharmaceutical company focused on the development of transformative treatments for metabolic and inflammatory diseases, has announced the successful closing of a $130 million Series B financing round. This significant capital infusion, led by Frazier Life Sciences, arrives less than a year after the company emerged from stealth with a $205 […]
